

PRESS RELEASE

Date 20 May 2016
Contact Investor Relations: Julien Vignot, Head Investor Relations, Galenica Group
Media Relations: Christina Hertig, Head Corporate Communications, Galenica Group
Subject The Galenica Group plans to take over SD wholesaler Pharmapool

Galenica aims to strengthen its logistics business

Galenica plans to acquire physicians wholesaler Pharmapool through its own wholesale company Galexis. As a result of the integration, both firms stand to benefit from interesting synergies arising from joint activities with self-dispensing physicians and a strengthened base for consolidating and further expanding the business. Pharmapool Ltd. will continue to offer its services on the market under its current name, while it will be integrated into the Galenica Group as part of the Services Business sector.

Pharmapool Ltd., headquartered in Widnau SG, supplies and supports medical practices with medicines, medical equipment, laboratory products and furnishings. The company also manages the Pharmapool central pharmacy in Heerbrugg SG. Founded in 1996, Pharmapool has a staff of some 100 employees and recorded sales of over CHF 100 million in 2015.

In a market characterised by increasing pressure on prices and margins, the integration of Pharmapool into the Galenica Group offers a solid foundation to secure and consolidate its market position over the long term. Pharmapool will remain an independent company within the Galenica Group and will continue to be managed by its current executive committee. This will ensure that Pharmapool can continue to offer its services to all interested market players in the future, while its customers can also benefit from potential synergies with Galexis over the medium term.

The acquisition will strengthen the logistics activities of the Galenica Santé Business unit. Pharmapool complements the portfolio of wholesaler Galexis and offers interesting potential synergies in an area of business and for expansion.

The shareholders of Pharmapool Ltd. were informed of Galenica's offer of over CHF 2,900 per share during the company's general meeting on 19 May 2016; the deadline for acceptance is 31 August 2016. If the shareholders accept the proposal, the acquisition will take place pending approval by the Competition Commission (COMCO).

For further information, please contact:

Media Relations:

Christina Hertig, Head Corporate Communications
Tel. +41 58 852 85 17
E-mail: media@galenica.com

Investor Relations:

Julien Vignot, Head Investor Relations
Tel. +41 58 852 85 29
E-mail: investors@galenica.com

Date 20 May 2016
Page 2/2
Subject The Galenica Group plans to take over SD wholesaler Pharmapool

Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group's income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).

For more information, please visit the company's website at www.galenica.com.